Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy

[1]  S. Bhatt,et al.  Etazolate rescues behavioral deficits in chronic unpredictable mild stress model: Modulation of hypothalamic–pituitary–adrenal axis activity and brain-derived neurotrophic factor level , 2013, Neurochemistry International.

[2]  S. Bhatt,et al.  Anxiolytic-like effect of etazolate, a type 4 phosphodiesterase inhibitor in experimental models of anxiety. , 2013, Indian journal of experimental biology.

[3]  M. Plotkine,et al.  Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice , 2013, Neuropharmacology.

[4]  S. Bhatt,et al.  Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage , 2013, Pharmacology Biochemistry and Behavior.

[5]  D. Pandey,et al.  Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor--an approach using rodent behavioral antidepressant tests battery. , 2012, European journal of pharmacology.

[6]  B. Frey,et al.  Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder , 2012, Oxidative medicine and cellular longevity.

[7]  J. O'Donnell,et al.  Effects of Repeated Treatment with Phosphodiesterase-4 Inhibitors on cAMP Signaling, Hippocampal Cell Proliferation, and Behavior in the Forced-Swim Test , 2011, Journal of Pharmacology and Experimental Therapeutics.

[8]  Lisa Goehler,et al.  In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[9]  M. Berk,et al.  A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  Nanxin Li,et al.  Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure , 2011, Biological Psychiatry.

[11]  G. Willemsen,et al.  Anxiety and depression in children and adults: influence of serotonergic and neurotrophic genes? , 2010, Genes, brain, and behavior.

[12]  M. Pando,et al.  Etazolate improves performance in a foraging and homing task in aged rats. , 2010, European journal of pharmacology.

[13]  R. Drucker-Colín,et al.  Antioxidant-Like Effects and Protective Action of Transcranial Magnetic Stimulation in Depression Caused by Olfactory Bulbectomy , 2010, Neurochemical Research.

[14]  F. Zitman,et al.  Salivary Cortisol Levels in Persons With and Without Different Anxiety Disorders , 2010, Psychosomatic medicine.

[15]  R. Drucker-Colín,et al.  Protective effect of nicotine on oxidative and cell damage in rats with depression induced by olfactory bulbectomy. , 2010, European journal of pharmacology.

[16]  D. Pandey,et al.  A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: Approaching early-onset antidepressants , 2010, Pharmacology Biochemistry and Behavior.

[17]  E. Nestler,et al.  Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior , 2010, Proceedings of the National Academy of Sciences.

[18]  G. Turecki,et al.  Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. , 2009, Journal of psychiatric research.

[19]  D. Pandey,et al.  1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay. , 2009, European journal of pharmacology.

[20]  N. Banu,et al.  In vivo antioxidant status: A putative target of antidepressant action , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  M. Cuesta,et al.  [Neurobiology of depression]. , 2002, Anales del sistema sanitario de Navarra.

[22]  X. Zhang,et al.  Increased Phospholipase A2 Activity and Inflammatory Response But Decreased Nerve Growth Factor Expression in the Olfactory Bulbectomized Rat Model of Depression: Effects of Chronic Ethyl-Eicosapentaenoate Treatment , 2009, The Journal of Neuroscience.

[23]  Junfa Li,et al.  Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress , 2008, Neurobiology of Disease.

[24]  F. Schweighoffer,et al.  Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing , 2008, Journal of neurochemistry.

[25]  C. Nemeroff,et al.  The link between childhood trauma and depression: Insights from HPA axis studies in humans , 2008, Psychoneuroendocrinology.

[26]  P. Montilla,et al.  Effect of 17β-estradiol on olfactory bulbectomy-induced oxidative stress and behavioral changes in rats , 2008, Neuropsychiatric disease and treatment.

[27]  M. Maes,et al.  The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. , 2008, Neuro endocrinology letters.

[28]  M. Radhakrishnan,et al.  Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models , 2008, Behavioural pharmacology.

[29]  H. Steinbusch,et al.  Effect of the COX-2 Inhibitor Celecoxib on Behavioural and Immune Changes in an Olfactory Bulbectomised Rat Model of Depression , 2007, Neuroimmunomodulation.

[30]  Ö. Aydemir,et al.  Serum brain-derived neurotrophic factor level in dysthymia: A comparative study with major depressive disorder , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[31]  C. Nemeroff.  The burden of severe depression: a review of diagnostic challenges and treatment alternatives. , 2007, Journal of psychiatric research.

[32]  K. Unsicker,et al.  Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy , 2007, Experimental Neurology.

[33]  R. Shelton.  The molecular neurobiology of depression. , 2007, The Psychiatric clinics of North America.

[34]  E. Castrén,et al.  Role of neurotrophic factors in depression. , 2007, Current opinion in pharmacology.

[35]  A. C. Uguz,et al.  Venlafaxine Modulates Depression-Induced Oxidative Stress in Brain and Medulla of Rat , 2007, Neurochemical Research.

[36]  J. Kelly,et al.  Antidepressants suppress production of the Th1 cytokine interferon-γ, independent of monoamine transporter blockade , 2006, European Neuropsychopharmacology.

[37]  M. Pedersen,et al.  Decreased Hippocampal Neurogenesis Following Olfactory Bulbectomy is Reversed by Repeated Citalopram Administration , 2006, Cellular and Molecular Neurobiology.

[38]  R. Duman,et al.  A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.

[39]  K. Fuxe,et al.  Corticosterone Actions on the Hippocampal Brain‐Derived Neurotrophic Factor Expression are Mediated by Exon IV Promoter , 2006, Journal of neuroendocrinology.

[40]  B. Leonard,et al.  The olfactory bulbectomised rat as a model of depression , 2005, Neuroscience & Biobehavioral Reviews.

[41]  C. Eap,et al.  Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response , 2005, Psychopharmacology.

[42]  F. Holsboer,et al.  Stress and the brain: from adaptation to disease , 2005, Nature Reviews Neuroscience.

[43]  M. Schwald,et al.  Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. , 2005, Brain research. Molecular brain research.

[44]  Thomas Michaelis,et al.  Alterations of neuroplasticity in depression: the hippocampus and beyond , 2004, European Neuropsychopharmacology.

[45]  Stuart Maudsley,et al.  BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders , 2004, Trends in Neurosciences.

[46]  T. Dawson,et al.  Cortical interneurons become activated by deafferentation and instruct the apoptosis of pyramidal neurons. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Victoria Arango,et al.  Volumetric Analysis of the Prefrontal Cortex, Amygdala, and Hippocampus in Major Depression , 2004, Neuropsychopharmacology.

[48]  J. D. den Boer,et al.  Molecular correlates of impaired prefrontal plasticity in response to chronic stress , 2003, Journal of neurochemistry.

[49]  J. O'Donnell,et al.  Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme , 2002, Neuropsychopharmacology.

[50]  K. Kanemoto,et al.  Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case–control study , 2002, International clinical psychopharmacology.

[51]  E. Bosmans,et al.  Anti-Inflammatory Effects of Antidepressants Through Suppression of the Interferon-γ/Interleukin-10 Production Ratio , 2001, Journal of clinical psychopharmacology.

[52]  Yvette I. Sheline,et al.  Amygdala core nuclei volumes are decreased in recurrent major depression , 1998, Neuroreport.

[53]  P. Willner.  Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation , 1997, Psychopharmacology.

[54]  R. Shelton,et al.  cAMP-dependent protein kinase activity in major depression. , 1996, The American journal of psychiatry.

[55]  E. Villacres,et al.  Induction of CRE-Mediated Gene Expression by Stimuli That Generate Long-Lasting LTP in Area CA1 of the Hippocampus , 1996, Neuron.

[56]  T. Palmer,et al.  Adenosine receptors , 1995, Neuropharmacology.

[57]  B. Leonard,et al.  The effects of chronic lithium chloride administration on some behavioural and immunological changes in the bilaterally olfactory bulbectomized rat , 1994, Journal of psychopharmacology.

[58]  R. Huganir,et al.  Functional modulation of GABAA receptors by cAMP-dependent protein phosphorylation. , 1992, Science.

[59]  K. Jacobson,et al.  Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors. , 1988, Biochemical pharmacology.

[60]  S. File,et al.  Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the rat , 1985, Journal of Neuroscience Methods.

[61]  H. Nakanishi,et al.  Effects of chronic administration of antidepressants on mouse-killing behavior (muricide) in olfactory bulbectomized rats , 1984, Pharmacology Biochemistry and Behavior.

[62]  S. Tannenbaum,et al.  Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. , 1982, Analytical biochemistry.

[63]  B. Cox,et al.  Olfactory projection systems, drugs and behaviour: A review , 1979, Psychoneuroendocrinology.

[64]  R. Porsolt,et al.  Behavioural despair in rats: a new model sensitive to antidepressant treatments. , 1978, European journal of pharmacology.

[65]  S. Hess,et al.  1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009)--a potent new inhibitor of cyclic 3',5'-nucleotide phosphodiesterases. , 1972, Biochemical pharmacology.

[66]  A. Sinha,et al.  Colorimetric assay of catalase. , 1972, Analytical biochemistry.

[67]  I. Fridovich,et al.  The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. , 1972, The Journal of biological chemistry.

[68]  B. Beer,et al.  Cyclic AMP and anxiety. , 1972, Psychosomatics.

[69]  E. Wills.  Mechanisms of lipid peroxide formation in animal tissues. , 1966, The Biochemical journal.

[70]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[71]  D. Pandey,et al.  Depressant‐like effects of parthenolide in a rodent behavioural antidepressant test battery , 2008, The Journal of pharmacy and pharmacology.

[72]  G. Kempermann,et al.  Neurogenesis in the adult hippocampus. , 2008, Cell and tissue research.

[73]  C. Pittenger,et al.  Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms , 2008, Neuropsychopharmacology.

[74]  S. Patten.  Confounding by severity and indication in observational studies of antidepressant effectiveness. , 2008, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[75]  G. Kempermann,et al.  Neurogenesis in the adult hippocampus , 2007, Cell and Tissue Research.

[76]  J. Malberg,et al.  Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. , 2005, Current pharmaceutical design.

[77]  H. Wachtel.  Dysbalance of neuronal second messenger function in the aetiology of affective disorders: A pathophysiological concept hypothesising defects beyond first messenger receptors , 2005, Journal of Neural Transmission.

[78]  H. Manji,et al.  Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. , 2001, Psychopharmacology bulletin.

[79]  J. Kelly,et al.  The olfactory bulbectomized rat as a model of depression: an update. , 1997, Pharmacology & therapeutics.

[80]  M. Maes.  Α Review on the Acute Phase Response in Major Depression , 1993, Reviews in the neurosciences.

[81]  B. Leonard,et al.  Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. , 1990, Pharmacology & therapeutics.

[82]  P. Goering,et al.  Through the looking Glass. , 1976, The Canadian nurse.

[83]  B. Pitt.  Psychopharmacology , 1968, Mental Health.